Colorectal cancer patients with poor responses to bevacizumab had increased ANG2 serum levels, and VEGF and ANG2 blockage in vivo delayed tumor growth, normalized tumor vasculature and increased the survival of mice with glioblastoma [73,74,75]. This evidence concerns the gene VEGFA and neoplasm.